Systolic dysfunction: Difference between revisions
Jump to navigation
Jump to search
Line 36: | Line 36: | ||
* Beta blockers for all patients except those who are hemodynamically unstable, or those who have rest dyspnea with signs of congestion. | * Beta blockers for all patients except those who are hemodynamically unstable, or those who have rest dyspnea with signs of congestion. | ||
* Aldosterone antagonist (low dose) for patients with rest dyspnea or with a history of rest dyspnea or for symptomatic patients who have suffered a recent myocardial infarction. | * Aldosterone antagonist (low dose) for patients with rest dyspnea or with a history of rest dyspnea or for symptomatic patients who have suffered a recent myocardial infarction. | ||
* | * Isorbide dinitrates-hydralazine combination for symptomatic heart failure patients who are African-American. | ||
* ARBs (angiotensin receptor blockers) as a substitute for patients intolerant of ACE inhibitors. | * ARBs (angiotensin receptor blockers) as a substitute for patients intolerant of ACE inhibitors. | ||
* Digoxin only for patients who remain symptomatic despite diuretics, ACE inhibitors and beta blockers or for those in atrial fibrillation. | * Digoxin only for patients who remain symptomatic despite diuretics, ACE inhibitors and beta blockers or for those in atrial fibrillation. |
Revision as of 01:27, 18 April 2009
Systolic dysfunction |
Overview
Left ventricular systolic dysfunction is the condition where the left ventricle can only manage to eject less than 40% (occasionally less than 35%) of the blood in it, with each contraction. The term is used when the echocardiogram shows this but the patient isn’t in overt heart failure.
Diagnosis
Treatment
Non-pharmacologic treatment
- Exercise
- Dietary changes
- Operative therapy: Surgery for underlying valvular heart diseases
Pharmacotherapy
For patients with systolic dysfunction (EF < 40%) who have no contraindications:
- ACE (angiotensin-converting enzyme) inhibitors for all patients.
- Beta blockers for all patients except those who are hemodynamically unstable, or those who have rest dyspnea with signs of congestion.
- Aldosterone antagonist (low dose) for patients with rest dyspnea or with a history of rest dyspnea or for symptomatic patients who have suffered a recent myocardial infarction.
- Isorbide dinitrates-hydralazine combination for symptomatic heart failure patients who are African-American.
- ARBs (angiotensin receptor blockers) as a substitute for patients intolerant of ACE inhibitors.
- Digoxin only for patients who remain symptomatic despite diuretics, ACE inhibitors and beta blockers or for those in atrial fibrillation.
- Diuretics for symptomatic patients to maintain appropriate fluid balance.
Device based therapy
- Implantable defibrillators considered for prophylaxis against sudden cardiac death in patients with EF ≤ 35%.
- Bi-ventricular pacemakers considered for patients requiring defibrillators who have symptomatic HF and QRS durations ≥ 120 msec.
References
Additional Readings
- Shekelle P, Rich M, Morton S, et al. Pharmacologic Management of Heart Failure and Left Ventricular Systolic Dysfunction: Effect in Female, Black, and Diabetic Patients, and Cost-Effectiveness. Evidence Report/Technology Assessment No. 82 (Prepared by the Southern California-RAND Evidence-based Practice Center under Contract No 290-97-0001). AHRQ Publication No. 03-E045. Rockville, MD: Agency for Healthcare Research and Quality. July 2003
- McAlister FA, Ezekowitz J, Dryden DM, Hooton N, Vandermeer B, Friesen C, Spooner C, Rowe BH. Cardiac Resynchronization Therapy and Implantable Cardiac Defibrillators in Left Ventricular Systolic Dysfunction. Evidence Report/Technology Assessment No. 152 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-02-0023). AHRQ Publication No. 07-E009. Rockville, MD: Agency for Healthcare Research and Quality. June 2007.